A detailed history of Mufg Securities Emea PLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Mufg Securities Emea PLC holds 136,269 shares of GILD stock, worth $12.8 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
136,269
Previous 192,706 29.29%
Holding current value
$12.8 Million
Previous $13.2 Million 13.61%
% of portfolio
0.45%
Previous 0.59%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $3.76 Million - $4.74 Million
-56,437 Reduced 29.29%
136,269 $11.4 Million
Q2 2024

Jul 31, 2024

BUY
$63.15 - $72.88 $11.9 Million - $13.8 Million
188,675 Added 4680.6%
192,706 $13.2 Million
Q1 2024

May 15, 2024

BUY
$71.58 - $87.29 $28,846 - $35,177
403 Added 11.11%
4,031 $295,000
Q4 2023

Feb 12, 2024

SELL
$73.27 - $83.09 $93,419 - $105,939
-1,275 Reduced 26.0%
3,628 $293,000
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $75,049 - $81,880
1,015 Added 26.11%
4,903 $367,000
Q2 2023

Aug 03, 2023

SELL
$76.01 - $86.7 $52,826 - $60,256
-695 Reduced 15.16%
3,888 $299,000
Q1 2023

May 10, 2023

BUY
$77.31 - $88.08 $277,542 - $316,207
3,590 Added 361.53%
4,583 $380,000
Q4 2022

Jan 24, 2023

SELL
$62.32 - $89.47 $362,702 - $520,715
-5,820 Reduced 85.42%
993 $85,000
Q3 2022

Nov 09, 2022

SELL
$59.54 - $68.01 $93,477 - $106,775
-1,570 Reduced 18.73%
6,813 $420,000
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $77,922 - $87,763
-1,350 Reduced 13.87%
8,383 $518,000
Q1 2022

May 10, 2022

SELL
$57.92 - $72.58 $886,176 - $1.11 Million
-15,300 Reduced 61.12%
9,733 $579,000
Q4 2021

Feb 11, 2022

SELL
$64.88 - $73.64 $77.7 Million - $88.2 Million
-1,198,309 Reduced 97.95%
25,033 $1.82 Million
Q3 2021

Nov 12, 2021

BUY
$67.69 - $73.03 $13.9 Million - $15 Million
205,573 Added 20.2%
1,223,342 $85.5 Million
Q2 2021

Jul 19, 2021

SELL
$63.47 - $69.35 $8.06 Million - $8.81 Million
-127,000 Reduced 11.09%
1,017,769 $70.1 Million
Q1 2021

May 11, 2021

BUY
$60.0 - $68.46 $10.2 Million - $11.7 Million
170,825 Added 17.54%
1,144,769 $74 Million
Q4 2020

Feb 11, 2021

BUY
$56.65 - $64.55 $14.5 Million - $16.5 Million
255,944 Added 35.65%
973,944 $56.7 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $3.78 Million - $4.75 Million
60,829 Added 9.26%
718,000 $45.4 Million
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $2.33 Million - $2.7 Million
32,171 Added 5.15%
657,171 $50.6 Million
Q1 2020

May 12, 2020

SELL
$62.63 - $80.22 $10.3 Million - $13.2 Million
-165,000 Reduced 20.89%
625,000 $46.7 Million
Q4 2019

Feb 11, 2020

BUY
$61.62 - $67.78 $30.1 Million - $33.1 Million
488,370 Added 161.91%
790,000 $51.3 Million
Q2 2019

Aug 13, 2019

SELL
$61.87 - $69.38 $15.2 Million - $17.1 Million
-246,100 Reduced 44.93%
301,630 $20.4 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $19 Million - $21.3 Million
304,450 Added 125.14%
547,730 $35.6 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $3.77 Million - $4.92 Million
62,257 Added 34.39%
243,280 $15.2 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $2.29 Million - $2.54 Million
32,187 Added 21.63%
181,023 $14 Million
Q2 2018

Aug 01, 2018

SELL
$64.88 - $75.68 $11.3 Million - $13.2 Million
-174,144 Reduced 53.92%
148,836 $10.5 Million
Q1 2018

May 01, 2018

SELL
$72.84 - $88.8 $12.8 Million - $15.6 Million
-175,600 Reduced 35.22%
322,980 $24.3 Million
Q4 2017

Feb 06, 2018

BUY
$71.15 - $83.52 $28 Million - $32.9 Million
393,700 Added 375.38%
498,580 $35.7 Million
Q3 2017

Nov 09, 2017

BUY
$72.11 - $85.47 $7.56 Million - $8.96 Million
104,880
104,880 $8.5 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Mufg Securities Emea PLC Portfolio

Follow Mufg Securities Emea PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Securities Emea PLC, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Securities Emea PLC with notifications on news.